Additionally, with rarer malignancies, the full impact of COVID-19 will be more challenging to identify unless multicenter, long-term studies are conducted so that subgroup analysis can be performed in a more meaningful manner, with a larger pooled cohort (e.g., antibody/IL-6 therapy in thyroid cancer). The gene discussed is IL6; the disease is thyroid gland carcinoma.